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Multiple sclerosis (MS) is a sophisticated dis-order in which the importance of immune system-related parameters in its pathogene-
sis is partially evident.1 Both the loss of myelin and cen-
tral nervous system (CNS) inflammation are frequent 
symptoms of MS.2 The proper mechanisms responsible 
for myelin degeneration in MS have yet to be clarified;2 
however, recent published studies state that cognate 
immune system parameters are closely involved in the 
pathogenesis and complications of MS.3 Accordingly, 
immune regulatory factors might influence the patho-
genesis of MS.3
Cytokines are key factors in an appropriate immune 
response in autoimmune diseases4,5 and interleukin 4 
(IL-4), a prevailing helper T cell (2TH) cytokine in 
regulation of 1TH responses of the CNS.6 Therefore, 
genetic factors that lead to a decreased cytokine expres-
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BACKGROUND AND OBJECTIVES: Immune system–related factors are important in the pathogenesis of mul-
tiple sclerosis (MS). Interleukin 4 (IL-4) as a helper T cell (2TH) cytokine is involved in the regulation of immune 
responses. Hence, this study was designed to explore the association between MS and polymorphisms in the 
-590 region of IL-4.
DESIGN AND SETTING: A descriptive study at Rafsanjan University of Medical Sciences, Rafsnajan from 
September 2009 to August 2010.
PATIENTS AND METHODS: Blood samples were collected from 100 MS patients and 150 healthy controls 
on EDTA precoated tubes. DNA was extracted and analyzed for IL-4 polymorphisms using restricted fragment 
length polymorphism in patients and controls. Demographic data were also collected by a questionnaire that 
was designed specifically for this study.
RESULTS: We observed a significant difference in the C/C, T/C, and T/T genotypes of the -590 region of IL-4 
between patients with MS and healthy controls (P<.001).
CONCLUSIONS: We conclude that functional polymorphisms of IL-4 possibly play a crucial role in the patho-
genesis of MS.
sion enable the immune system to induce a vigorous im-
mune response against CNS antigens in patients with 
MS.7 The involvement of IL-4 in immunological dis-
orders including MS,7 systemic lupus erythematosus,8 
nephrotic syndrome,9 graft rejection,10 asthma,11 and 
type 1 diabetes12 is well documented. The human IL-4 
gene is located on a cluster of cytokine genes on the q 
arm of chromosome 5 (5q31.1). It is approximately 10 
kb in size with 4 exons and 3 introns (a and b). The IL-4 
promoter region that extends to about 500 bp from the 
“TATA”-like sequence contains 5 polymorphic sites. 
The -590C/T single-nucleotide polymorphism is the 
most common IL-4 promoter olymorphic site (c). The 
paramount role of IL-4 as an inhibitory cytokine in au-
toimmunity and inflammation13 explain the challenges 
of this cytokine on the pathogenesis of some diseases 
including MS. Previous studies revealed that IL-4 ex-
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pression could be regulated by its polymorphisms in the 
-590 region.6,14 Therefore, we aimed to investigate the 
polymorphisms in the -590 region of this cytokine in 
relapse-remitting multiple sclerosis (RRMS).
PATIENTS AND METHODS
Collection of samples
Specimens were collected from 100 relapsing-remit-
ting patients with MS and 150 healthy controls dur-
ing 2008–2009 in Rafsanjan University of Medical 
Sciences. The occurrence of MS was diagnosed by a 
neurologist according to clinical and paraclinical find-
ings (magnetic resonance imaging study, oligoclonal 
bands in cerebrospinal fluid, and evoked potentials) 
based on the McDonald criteria.15 Healthy control 
cases were also selected within the Rafsanjan popu-
lation and matched by sex, age, and socioeconomic 
status following approval by Rafsanjan University of 
Medical Sciences Ethical Committee. Written con-
sent forms were filled out by both patients and con-
trols prior to specimen collection. The socioeconomic 
status was based on monthly income and education 
levels.
DNA extraction and detection of polymorphisms
The peripheral blood was collected on EDTA precoat-
ed tubes and then genomic DNA was extracted by a 
commercial kit (Bioneer, South Korea). The extracted 
DNA samples were then stored at –20°C for further 
use.
IL-4 (-590C/T) gene polymorphism was ana-
lyzed by the polymerase chain reaction (PCR)-
restricted fragment length polymorphism method. 
The sequences of primers were as follows: sense - 
5’-TAAACTTGGGAGAACATGGT-3’ and anti-
sense - 5’-TGGGGAAAGATAGAGTAAT-3’. The 
PCR mixture was made up by addition of the follow-
ing reagents to a 0.2 mL microcentrifuge tube on ice: 
2.5 µL of Taq DNA polymerase buffer (10×), 0.5 µL 
of MgCl2 (stock concentration 1.5 mM), 0.5 µL of 
each dNTP [(dATP, dCTP, dGTP, and dTTP) stock 
concentration of 10 mM], 1 µL of each primer [(for-
ward and reverse), stock concentration of 25 ng/µL], 1 
µL of prepared DNA, and sterile double distilled wa-
ter to a final volume of 25 µL. The PCR condition was 
an initial denaturation at 95°C for 5 minutes, followed 
by 35 cycles of melting at 95°C for 50 seconds, anneal-
ing at 53°C for 50 seconds, and extension at 72°C for 
40 seconds, with a final extension step of 5 minutes at 
72°C using thermal cycler (C1000; Bio-Rad, USA). 
The PCR product of IL-4 (-590C/T) was a 195-bp 
fragment and was digested with AvaII into 175- and 
20-bp fragments. The digested products were run on 
a 2.5% agarose gel (Cinnagen, Iran) and studied on 
Chemi-Doc model XRS (Bio-Rad) after staining with 
ethidium bromide. The assay yielded a single 195-bp 
band related to heterozygote C/T genotype; 2 bands 
of 20 and 175 bp related to the hemozygote CC geno-
type; and 3 bands of 20, 175, and 195 bp correspond-
ed to homozygote TT genotype.
Statistical analysis
The Hardy-Weinberg equilibrium was assessed using 
genotype data. Allele and genotype frequencies were 
calculated in patients and healthy controls by direct 
gene counting. The statistical analysis of the differenc-
es between groups was determined by the chi-square 
test  using EPI 2000 and SPSS software version 13 
(IBM Corp., Armonk, NY USA). A P value less than 
.05 was considered as significant.
RESULTS
The evaluation of the polymorphisms in -590 of IL-4 
Table 2. demographic and socioeconomic conditions of multiple sclerosis patient and 
controls.
Variant Healthy control MS patient P value
Age 31 (8) 31 ( 6) .85
Sex
   Female 69 (46%) 45 (45%)
.90
   Male 81 (54%) 55 (55%)
Socioeconomic status
   Weak 31 (21%) 22 (22%)
.90   Medium 72 (48%) 47 (47%)
   high 47 (31%) 31 (31%)
Table 1. Frequency of polymorphisms of il-4 gene in multiple sclerosis  patients and 
controls.
Condition Genotype
(n, %) Patients Control P value
C/C 76 (76%) 108 (72%) <.001
T/C 23 (23%) 38 (25.3%)
T/T 1 (1%) 4 (2.7%) 
Alleles
   C 175 (87.5%) 254 (84.6%) <.001
   T 25 (12.5%) 46 (15.4%)
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by AvaII restriction enzyme showed that the preva-
lence of C/C genotype was 76 (76%) in patients with 
RRMS and 108 (72%) in controls. We found that 
the frequency of T/C genotype was 23 (23%) and 
38 (25.3%) in patients with RRMS and controls, re-
spectively. The frequency of T/T genotype in patients 
with RRMS was 1 (1%), whereas the frequency of 
this genotype in controls was 4 (2.7%) (Table 1). The 
statistical analysis of our data confirmed a significant 
difference between two groups in genotypes (P<.001). 
The frequency of the C allele was 175 (87.5%) and 
254 (84.6%) in patients with RRMS and controls, 
respectively. Twenty-five (12.5%) cases of T allele 
were observed in patients, whereas the frequency 
of this allele was 46 (15.4%) in controls. To test for 
Hardy-Weinberg equilibrium, the chi-square in the 
patients group (c2=0.058, P=86.5) and in the con-
trol (c2=0.036, P=88.5) strongly indicated that both 
groups were in Hardy-Weinberg equilibrium. The 
statistical analysis of alleles indicated no significant 
difference between patients with RRMS and controls 
(P= .374) (Table 1). The calculated odds ratio of al-
leles was 0.79 for patients with RRMS and controls. 
There was no statistically significant difference be-
tween groups in mean age (P=.85), gender (P=.90), 
and or socioeconomic status of the participants 
(P=.90) (Table 2).
DISCUSSION
The pivotal role of the immune system in the etiology 
and pathogenesis of MS are well documented.16-18 The 
crucial role of the cytokine network in the immune re-
sponse is also documented.4,19 It is well known that 
several factors—from infectious agents, hormonal 
conditions, to cytokine gene polymorphisms—control 
expression and secretion of cytokines.19 The results 
of our study showed that there was a clear significant 
difference between control subjects and patients with 
RRMS in polymorphisms in the -590 region of IL-
4. Previous studies have shown a close correlation 
between the C/C genotype and decreased expression 
of IL-4.20,21 In this investigation, we observed that 
the C/C genotype is more frequent in patients with 
RRMS than controls. Therefore, based on our results, 
it seems that IL-4 gene polymorphisms can influ-
ence the pathogenesis of MS in our study population 
(south-eastern Iranian patients). In contrast to our 
results, Kamali et al showed that the polymorphisms 
in this region of IL-4 were not associated with MS 
in Shiraz city of Iran (a south-central part of Iran).22 
This discrepancy between our results and the find-
ings of Kamali et al could be explained by the fact that 
some parts of the Shiraz population are mixed, with 
both Iranian and Turk ethnic groups, which differ in 
race and genetic constitution from our study popula-
tion. Furthermore, Kamali et al studied IL-4 polymor-
phisms in all different phases of MS,22 whereas all of 
our patients were in relapsing-remitting phases. Our 
results may reveal that IL-4 polymorphisms are more 
related to this type of disease rather than the other 
phases of MS. 
These data may help clinicians to predict the begin-
ning of the relapsing-remitting course of MS. Some 
studies have indicated that IL-4 -590 polymorphisms 
are associated with MS, which is consistent with out 
results.6,7,23,24 For instance, Urcelay et al showed that 
these polymorphisms are associated with MS in the 
Spanish population.6 An investigation in the Italian 
population also showed a significant correlation be-
tween IL-4 polymorphisms and late onset of MS.23 
The relationship between other polymorphisms in 
the IL-4 gene and MS also was reported by other in-
vestigators.7,24 Therefore, it seems that IL-4 polymor-
phisms can significantly affect the expression of IL-4, 
and hence could presumably be involved in MS pro-
gression.
Overall, further studies are needed on patients with 
MS in different phases of MS with a wider sample size 
to differentiate between various MS phases according 
to the polymorphisms in Iranian patients with MS.
Acknowledgments
Authors of this article appreciate all MS patients and 
healthy control individuals who voluntarily attended this 
research project. This project was supported by a grant 
from Rafsanjan University of Medical Sciences.
original article il4 polyMorphiSMS And MS
Ann Saudi Med 2012 March-April www.annsaudimed.net130
1. o’Keeffe J, Gately CM, Counihan T, hennessy 
M, leahy T, Moran Ap, et al. T-cells expressing 
natural killer (nK) receptors are altered in multiple 
sclerosis and responses to alpha-galactosylce-
ramide are impaired. J neurol Sci 2008;275:22-8.
2. lindvall o, Kokaia Z. Stem cells for the treatment 
of neurological disorders. nature 2006;441:1094-6.
3. Baker BJ, Akhtar ln, Benveniste En. SoCS1 
and SoCS3 in the control of CnS immunity. Trends 
immunol 2009;30:392-400.
4. Arababadi MK, nosratabadi r, hassanshahi 
G, yaghini n, pooladvand V, Shamsizadeh A. ne-
phropatic complication of type-2 diabetes is fol-
lowing pattern of autoimmune diseases? diabetes 
res Clin pr 2010;87:33-7.
5. Arababadi MK, Mosavi r, Khorramdelazad h, 
yaghini n, Zarandi Er, Araste M, et al. Cytokine 
patterns after therapy with Avonex(r), rebif(r), 
Betaferon(r) and CinnoVex in relapsing-remitting 
multiple sclerosis in iranian patients. Biomark 
Med 2010;4:755-9.
6. Urcelay E, Santiago Jl, Mas A, Martinez A, de 
las heras V, Arroyo r, et al. role of interleukin 4 
in Spanish multiple sclerosis patients. J neuroim-
munol 2005;168:164-7.
7. Kantarci oh, Schaefer-Klein Jl, hebrink dd, 
Achenbach SJ, Atkinson EJ, McMurray CT, et al. 
A population-based study of il4 polymorphisms in 
multiple sclerosis. J neuroimmunol 2003;137:134-
9.
8. Wu MC, huang CM, Tsai JJ, Chen hy, Tsai FJ. 
polymorphisms of the interleukin-4 gene in chi-
nese patients with systemic lupus erythematosus 
in Taiwan. lupus 2003;12:21-5.
9. liu hM, Shen Q, Xu h, yang y. [Significance of 
polymorphisms in variable number of tandem re-
peat region of interleukin-4 gene in recurrence of 
childhood steroid sensitive nephrotic syndrome]. 
Zhonghua Er Ke Za Zhi 2005;43:431-3.
10. Amirzargar M, yavangi M, Basiri A, Mogha-
dam Sh, Khosravi F, Solgi G, et al. Genetic asso-
ciation of interleukin-4, interleukin-10, and trans-
forming growth factor-beta gene polymorphism 
with allograft function in renal transplant patients. 
Transplant proc 2007;39:954-7.
11. Wang Xh, Zhao W, liu SG, Feng Xp. [Correla-
tion of il-4 and il-13 gene polymorphisms with 
asthma and total serum igE levels]. Zhonghua Jie 
he he hu Xi Za Zhi 2009;32:161-4.
12. Bugawan Tl, Mirel dB, Valdes AM, panelo A, 
pozzilli p, Erlich hA. Association and interaction 
of the il4r, il4, and il13 loci with type 1 diabetes 
among Filipinos. Am J hum Genet 2003;72:1505-14.
13. Arababadi MK, pourfathollah AA, Jafarzadeh 
A, hassanshahi G, daneshmandi S, Zarandi Er, et 
al. Evaluation of relation between polymorphisms 
in -590 region of il-4 and occult hBV infection. J 
Guil Univ Med Sci 2009;18:1-8.
14. Arababadi MK, pourfathollah AA, danesh-
mandi S, hassanshahi G, Zarandi Er, Shamsiza-
deh A, et al. Evaluation of relation between il-4 
and iFn-g polymorphisms and type 2 diabetes. 
iJBMS 2009;12:100-4.
15. Mcdonald Wi, Compston A, Edan G, Goodkin 
d, hartung hp, lublin Fd, et al. recommended di-
agnostic criteria for multiple sclerosis: Guidelines 
from the international panel on the diagnosis of 
multiple sclerosis. Ann neurol 2001;50:121-7.
16. Arababadi MK, hassanshahi G, Azin h, Sale-
habad VA, Araste M, pourali r, et al. no asso-
ciation between CCr5 ? 32 mutation and multiple 
sclerosis in patients of south-eastern of iran. lab 
Medicine 2010;41:31-3. 
17. pulkkinen K, luomala M, Kuusisto h, lehtimaki 
T, Saarela M, Jalonen To, et al. increase in CCr5 
delta32/delta32 genotype in multiple sclerosis. 
Acta neurol Scand 2004;109:342-7.
18. Welsh CJ, Steelman AJ, Mi W, young Cr, 
Storts r, Welsh Th Jr, et al. neuroimmune inter-
actions in a model of multiple sclerosis. Ann n y 
Acad Sci 2009;1153:209-19.
19. Arababadi MK, naghavi n, hassanshahi G, 
Mahmoodi M. is CCr5-delta32 mutation associat-
ed with diabetic nephropathy in type 2 diabetes? 
Ann Saudi Med 2009;29:413.
20. rosenwasser lJ, Klemm dJ, dresback JK, in-
amura h, Mascali JJ, Klinnert M, et al. promoter 
polymorphisms in the chromosome 5 gene clus-
ter in asthma and atopy. Clin Exp Allergy 1995;25 
Suppl 2:74-8; discussion 95-6.
21. Gonzales Jr, Groger S, haley G, Bodeker rh, 
Meyle J. The interleukin-4 -34TT and -590TT geno-
type is correlated with increased expression and 
protein production in aggressive periodontitis. 
Mol immunol 2009;1:1.
22. Kamali-Sarvestani E, nikseresht A, Aflaki E, 
Sarvari J, Gharesi-Fard B. TnF-alpha, TnF-beta 
and il-4 gene polymorphisms in iranian patients 
with multiple sclerosis. Acta neurol Scand 
2007;115:161-6.
23. Vandenbroeck K, Martino G, Marrosu M, Con-
siglio A, Zaffaroni M, Vaccargiu S, et al. occur-
rence and clinical relevance of an interleukin-4 
gene polymorphism in patients with multiple scle-
rosis. J neuroimmunol 1997;76:189-92.
24. Suppiah V, Goris A, Alloza i, heggarty S, du-
bois B, Carton h, et al. polymorphisms in the in-
terleukin-4 and il-4 receptor genes and multiple 
sclerosis: A study in Spanish-Basque, northern 
irish and Belgian populations. int J immunogenet 
2005;32:383-8.
REfERENCES
